BIOAFFINITY TRIGGERED MACD & KDJ DEATH CROSS ON 15MIN CHART

As of October 7, 2025, at 10:15, the 15-minute chart for bioAffinity has triggered a MACD Death Cross and a KDJ Death Cross. This indicates that the stock price has the potential to continue declining, with a shift in momentum towards the downside and a higher likelihood of further decreases in the stock price.

San Antonio, TX - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) has announced significant growth in its CyPath® Lung diagnostic test for lung cancer, reflecting a 95% increase in sales during the third quarter of 2025 compared to the previous quarter. This growth is attributed to the increasing adoption of the test by Veterans’ hospitals and market expansion in the mid-Atlantic region. Over the first nine months of 2025, sales of CyPath® Lung rose by 97% compared to the same period in 2024 bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025^[1].

Maria Zannes, President and CEO of bioAffinity Technologies, commented on the growth, stating, "The continued acceleration in CyPath® Lung adoption underscores the growing physician confidence in our test to detect lung cancer at its earliest, most treatable stages. Physicians are equally impressed by CyPath® Lung’s ability to save patients from unnecessary invasive procedures when the nodule is benign."

The company's Chief Medical Officer, Gordon Downie, MD, PhD, further highlighted the real-world impact of CyPath® Lung, noting that it has detected early-stage lung cancer in patients where other diagnostics suggested a low probability of cancer, and spared patients from invasive procedures when the result was negative. The test has also proven effective in detecting lung cancer earlier in difficult-to-diagnose ground-glass nodules bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025^[1].

Despite the positive financial performance, technical indicators for bioAffinity's stock suggest a potential decline. As of October 7, 2025, at 10:15, the 15-minute chart for bioAffinity triggered a MACD Death Cross and a KDJ Death Cross, indicating a shift in momentum towards the downside and a higher likelihood of further decreases in the stock price.

Forward-looking statements highlight the risks and uncertainties associated with the company's ability to continue sales growth in 2025 and beyond bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025^[1].